Plasma Metabolomics Identifies Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction
Plasma-Metabolomik identifiziert Signaturen zur Unterscheidung von Herzinsuffizienz mit reduzierter und erhaltener Ejektionsfraktion
ESC Heart Failure · 01.08.2025 · 12 (4) · 2803-2813
DOI: 10.1002/ehf2.15285 ↗Auf einen Blick
Bei 787 Plasma-Proben unterschieden sich Metabolit-Signaturen zwischen HFrEF und HFpEF. Mehrere Acylcarnitine und Aminosäurederivate waren erhöht; 3-Hydroxybutyrat war nur bei HFrEF erhöht.
Fragestellung
Lassen sich mit quantitativer Plasma-Metabolomik Biomarker finden, die HFrEF und HFpEF unterscheiden?
Methode
Plasma-Metabolomik und Proteomik in Proben aus dem Penn Medicine BioBank von HFrEF-, HFpEF- und Kontrollpersonen; Analyse von 90 Metaboliten.
Ergebnisse
Untersucht wurden 787 Proben: HFrEF n = 219, HFpEF n = 357, Kontrollen n = 211. Ungesättigte mittelkettige/lange Acylcarnitine waren bei HFrEF erhöht; ADMA war nur bei HFpEF erhöht; 3-HBA war nur bei HFrEF erhöht.
Schlussfolgerung der Autor:innen
Die Ergebnisse identifizieren gemeinsame und potenziell unterscheidende Plasma-Signaturen für HFrEF und HFpEF. Marker des ketogenen Stoffwechsels zeigten sich als einzigartige Signaturen bei HFrEF.
Kernaussagen
- 787 Plasma-Proben wurden metabolomisch untersucht.
- Mehrere Acylcarnitine und Aminosäurederivate waren bei HF erhöht.
- 3-Hydroxybutyrat war nur bei HFrEF erhöht.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 15.04.2025. Verfasst von Fawaz Naeem und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Heart Failure, Metabolomics, Stroke Volume, Ventricular Function, Left. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, NCATS NIH HHS.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Two general phenotypes of heart failure (HF) are recognized: HF with reduced ejection fraction (HFrEF) and with preserved EF (HFpEF). To develop phenotype-specific approaches to treatment, distinguishing biomarkers are needed. The goal of this study was to utilize quantitative metabolomics on a large, diverse population to replicate and extend existing knowledge of the plasma metabolic signatures in human HF.
Methods
Plasma metabolomics and proteomics was conducted on 787 samples collected by the Penn Medicine BioBank from subjects with HFrEF (n = 219), HFpEF (n = 357) and matched controls (n = 211). A total of 90 metabolites were analysed, comprising 28 amino acids, 8 organic acids and 54 acylcarnitines. Seven hundred thirty-three of these samples also underwent proteomic profiling via the O-Link proteomics panel.
Results
Unsaturated forms of medium-/long-chain acylcarnitines were elevated in the HFrEF group. Amino acid derivatives, including 1- and 3-methylhistidine, homocitrulline and symmetric and asymmetric (ADMA) dimethylarginine were elevated in HF, with ADMA elevated uniquely in HFpEF. While the branched-chain amino acids (BCAAs) were minimally changed, short-chain acylcarnitine species indicative of BCAA catabolism were elevated in both HF groups. 3-hydroxybutyrate (3-HBA) and its metabolite, C4-OH carnitine, were uniquely elevated in the HFrEF group. Linear regression models demonstrated a significant correlation between plasma 3-HBA and N-terminal pro-brain natriuretic peptide in both forms of HF, stronger in HFrEF.
Conclusions
These results identify plasma signatures that are shared as well as potentially distinguish HFrEF and HFpEF. Metabolite markers for ketogenic metabolic re-programming were identified as unique signatures in the HFrEF group, possibly related to increased levels of BNP. Our results set the stage for future studies aimed at assessing selected metabolites as relevant biomarkers to guide HF phenotype-specific therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Drug Safety Research and Development, Pfizer Inc, Groton, Connecticut, USA.
- Translational Clinical Sciences, Pfizer Inc, Groton, Connecticut, USA.
- Non-Clinical Statistics, Data Sciences and Analytics, Pfizer Inc, Cambridge, Massachusetts, USA.
- Pfizer Internal Medicine, Clinical Development, Cambridge, Massachusetts, USA.
- Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Daniel P Kelly
Förderung
- NHLBI NIH HHS
- NIH HHS
- NCATS NIH HHS
- NIDDK NIH HHS
- NCI NIH HHS
- Pfizer
- National Institutes of Health
Zitieren
APA
Naeem, F., Leone, T. C., Petucci, C., Shoffler, C., Kodihalli, R. C., Hidalgo, T., Tow-Keogh, C., Mancuso, J., Tzameli, I., Bennett, D., Groarke, J. D., Roth Flach, R. J., Rader, D. J., & Kelly, D. P. (2025). Plasma Metabolomics Identifies Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction. ESC Heart Failure, 12(4), 2803-2813. https://doi.org/10.1002/ehf2.15285
Vancouver
Naeem F, Leone TC, Petucci C, Shoffler C, Kodihalli RC, Hidalgo T, et al. Plasma Metabolomics Identifies Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction. ESC Heart Failure. 2025;12(4):2803-2813. doi:10.1002/ehf2.15285
BibTeX
@article{Naeem2025,
author = {Naeem, Fawaz and Leone, Teresa C and Petucci, Christopher and Shoffler, Clarissa and Kodihalli, Ravindra C and Hidalgo, Tiffany and Tow-Keogh, Cheryl and Mancuso, Jessica and Tzameli, Iphigenia and Bennett, Donald and Groarke, John D and Roth Flach, Rachel J and Rader, Daniel J and Kelly, Daniel P},
title = {Plasma Metabolomics Identifies Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {4},
pages = {2803--2813},
doi = {10.1002/ehf2.15285}
}
EUVIMED